Jack Anthony

Mr. Anthony has spent over 44 years in the healthcare industry. He is currently the Founder/Principal of BioMentorz, a small company bio-consulting firm. He was formerly the CEO of Osprey Pharmaceuticals USA and of Pharmix (now Numerate). He has also served as a member of the Board of Vaxgen, a public US company. Prior to his CEO roles, Mr. Anthony spent over 15 years conducting biotech business development and marketing at a variety of biotech companies. He was Senior Vice President of Business Development at Saegis Pharmaceuticals (now Lundbeck). He was a key player in the buyout of Tularik (by Amgen) where he led the Business and Commercial Group. In the fifteen years prior to Tularik he was the senior executive business development officer at FibroGen, Inc., Cell Therapeutics, Inc., Inhale, Applied Immune Sciences (now at Sanofi-Aventis) and General Manager of ExViT, the AIS subsidiary focused on the delivery of ex-vivo cell therapies.

Mr. Anthony began his life sciences career at Baxter Healthcare Corporation and for 17 years held various sales, marketing and general management positions in the U.S. and internationally. He departed Baxter as Vice President of the Blood Therapy Group. Jack holds a BS in Zoology from Allegheny College and served as a U.S. Navy Officer for five years.